ArticleBMC pediatrics2026
Posaconazole therapeutic drug monitoring in pediatrics: a single-center retrospective study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive fungal infections are associated with high morbidity and mortality in immunosuppressed pediatric patients. Posaconazole is commonly used for both prophylaxis and treatment of invasive fungal infections. The study's primary objective was to determine the percentage (%) of patients that achieved posaconazole therapeutic targets. The secondary objective was to evaluate the relationship between posaconazole exposure and clinical outcomes or toxicity.
methodsThis single-center retrospective study included pediatric patients from 1 month to 18 years who received posaconazole for prophylaxis fungal infections. Data were collected from the hospital's electronic medical records and included age, gender, height, weight, laboratory values, dose, dosing frequency, trough concentrations, drugs interact with posaconazole. Primary outcomes included the percentage of patients who achieved target trough levels of posaconazole. We also looked at factors correlated to trough concentrations, which included: dose, age, weight, presence of drug interactions and laboratory values such aspartate transaminase (AST), alanine transaminase (ALT), and albumin levels. Secondary outcomes included the correlation between posaconazole trough concentrations, clinical or microbiologic outcomes, and toxicity.
resultsA total of 69 trough plasma concentrations were measured across 42 patients. Among these, 27 patients had a second trough level assessed. The mean concentration of the initial trough was 1.4 ± 1.3 mg/L (mean ± SD), with concentrations ranging from 0.2 to 6.2 mg/L. The mean concentration of the second trough was 0.99 ± 0.8 mg/L, ranging from 0.2 to 4.1 mg/L. For the initial trough concentrations, 59.5% fell within the therapeutic range. A total of 10 patients (23.8%) experienced adverse events that were attributed to posaconazole.
conclusionPosaconazole trough concentrations vary in pediatric patients and around half of the patients achieved therapeutic concentrations with initial doses with minimal adverse events reported.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.